

# ANALYSIS OF HYBRID TOTAL HIP REPLACEMENT USING THE C-STEM® AMT FEMORAL COMPONENT AND THE PINNACLE® ACETABULAR SYSTEM IN THE NATIONAL JOINT REGISTRY FOR ENGLAND, WALES, NORTHERN IRELAND AND THE ISLE OF MAN

Jack Mantel, BA, Associate Director HEMA | *DePuy Synthes*  
John Leopold MS, Biostatistician | *DePuy Synthes Joint Reconstruction*

## Introduction

National joint registries provide valuable and generalizable information on the revision rates / survivorship of newer and older implants alike. Typically they include large cohorts with contributions from all surgeons, irrespective of experience level. The National Joint Registry for England, Wales, Northern Ireland and the Isle of Man (NJR) has been in operation since 2003 and in that time has collected data on over 890,000 primary total hip replacements.<sup>1</sup>

A hybrid total hip replacement (THR) uses a cementless modular acetabular cup and a cemented femoral stem. Up to the end of 2016, hybrid THR accounted for 170,589 procedures on the NJR, with a steady uptake in adoption from 12.3% in 2003 to 19.2% in 2016.<sup>1</sup> In 2016, the majority of hybrid THRs utilised a Metal-on-Polyethylene (55.2%) articulation, with smaller proportions for Ceramic-on-Polyethylene (38.1%) and Ceramic-on-Ceramic (6.0%).

The use of Hybrid THR is intended to combine the potential benefits of a cemented stem and a cementless acetabular implant. Development of cementing techniques in the 1970s led to improvements in the durability of cemented femoral components, but even into the 1990s this did not appreciably alleviate the problem of late loosening associated with cemented acetabular cups.<sup>2-3</sup> Cementless fixation on the acetabular side has demonstrated excellent long-term fixation<sup>4-5</sup> and has provided the surgeon with greater flexibility in choice of bearing size and material. It also presents more options when dealing with challenging anatomies or diagnoses.<sup>6</sup>

In a study based on data from the New Zealand Joint Registry, Hooper et al<sup>7</sup> compared the patient time incidence rates (PTIR) across four fixation types. The authors found a lower overall revision rate for hybrid when compared to cementless and the difference was significant ( $p < 0.01$ ). Hybrid was also found to have the lowest revision rate in subjects younger than 55 (compared to cemented -  $p < 0.012$ ) and in the age range of 55-64 (compared to cementless -  $p < 0.007$ ). Good mid- and long-term outcomes in prospective clinical studies are also available elsewhere in the literature.<sup>8-10</sup>

The purpose of this analysis is to examine the results of the hybrid combination of the C-STEM AMT Cemented Stem with the PINNACLE Cementless Acetabular System. In addition to the published NJR reports, data is also made available for post-marketing surveillance from the NJR Supplier Feedback system, downloaded by DePuy Synthes on 10th April 2018.<sup>11</sup> This additional information provides detailed data on all C-STEM AMT implantations included on the registry. Sub-group analysis has been performed on the different PINNACLE bearing options.

## Results

In total the dataset records 11028 hybrid THR cases in which a C-STEM AMT Stem had been used with a PINNACLE Acetabular Cup. The mean age of the cohort was 70 years (range 18-98) and there were 6914 females and 4114 males. 90% of cases had osteoarthritis listed as at least one of the primary diagnoses.<sup>11</sup>

The follow-up for the cohort extends to 12 years and the patient time incidence rate (PTIR) is 0.37 (95% CI 0.30, 0.43) revisions per 100 observed component

years. A Kaplan-Meier analysis was undertaken to estimate the cumulative revision rate (CRR) with an end point of revision of any component for any cause and the annual estimates are provided in Table 1 with results truncated when fewer than 40 implants remained at risk, as per Lettin et al.<sup>12</sup> Survivorship analysis was also run on the different bearing options, also detailed in Table 2. There were a total of 121 revision procedures recorded and it is noted from the survivorship analysis that only six revisions have taken place after 7 years from a total of 879 subjects at risk.

Group	1 year	2 years	3 years	5 years	7 years	10 years
C-STEM AMT PINNACLE n=11028	0.61% (0.48, 0.78%) n=8521	0.89% (0.72, 1.10%) n=6264	1.12% (0.91, 1.38%) n=4376	1.53% (1.23, 1.89%) n=1968	1.99% (1.55, 2.55%) n=879	2.82% (2.03, 3.91%) n=279
Metal on Poly n=6039	0.68% (0.50, 0.93%) n=4817	0.98% (0.75, 1.29%) n=3609	1.25% (0.96, 1.62%) n=2506	1.64% (1.24, 2.16%) n=1101	1.91% (1.40, 2.59%) n=443	2.77% (1.66, 4.60%) n=133
Ceramic on Ceramic n=1415	0.43% (0.19, 0.96%) n=1297	0.59% (0.30, 1.18%) n=1162	0.78% (0.42, 1.46%) n=998	1.37% (0.82, 2.29%) n=623	1.82% (1.08, 3.04%) n=324	2.92% (1.71, 4.94%) n=136
Ceramic on Poly n=3508	0.58% (0.37, 0.91%) n=2347	0.88% (0.59, 1.32%) n=1448	1.07% (0.70, 1.62%) n=836	1.23% (0.79, 1.92%) n=226	2.64% (1.20, 5.74%) n=100	n/a

**Table 1:** C-STEM AMT and PINNACLE Primary THR: Cumulative Revision Rate Estimates by bearing articulation. (2018 NJR) (95% CI), n with later follow up.

## Conclusion

Hybrid THR was introduced in order to combine the perceived advantages of cemented femoral stems with the flexibility and long-term durability of cementless acetabular cups.<sup>8-10</sup> The cumulative revision rate estimates calculated from the NJR dataset for the

combination of the C-STEM AMT femoral stem and the PINNACLE Acetabular system show satisfactory durability out to ten years, and compare favourably at long term follow-up to the overall class of hybrid THR from the NJR,<sup>13</sup> the Australian Orthopaedic Association National Joint Replacement Registry,<sup>14</sup> and the New Zealand Joint Registry.<sup>15</sup>

## References

1. National Joint Registry for England, Wales, Northern Ireland and the Isle of Man, 14th Annual Report, 2017. Tables 3.3 and 3.4. Available from [www.njrreports.org.uk](http://www.njrreports.org.uk)
2. The effect of improved cementing techniques on component loosening in total hip replacement. An 11-year radiographic review. Mulroy RD Jr, Harris WH. *J Bone Joint Surg Br.* 1990;72(5):757-60.
3. Hybrid Total Hip Replacement. Macaulay W, Parks ML. *Operative Techniques in Orthopaedics*, 2000;10(2):115-119.
4. A randomised prospective evaluation of ceramic-on-ceramic and ceramic-on-highly cross-linked polyethylene bearings in the same patients with primary cementless total hip arthroplasty. Kim Y H, Park J W, Kulkarni SS, Kim Y H. *Int Orthop.* 2013;37(11):2131-7
5. Polyethylene wear and osteolysis after cementless total hip arthroplasty with alumina-on-highly cross-linked polyethylene bearings in patients younger than thirty years of age. Kim YH, Park JW, Patel C, Kim DY. *J Bone Joint Surg Am.* 2013;95:1088-93.
6. Learmonth ID, Young C, Rorabeck C. The operation of the century: total hip replacement. *Lancet* 2007;370:1508-19.
7. Revision following cemented and uncemented primary total hip replacement - A Seven-Year Analysis from the New Zealand Joint Registry. Hooper GJ, Rothwell AG, Stringer M, Frampton C. *J Bone Joint Surg Br.* 2009;91(4):451-8
8. Primary hybrid total hip replacement, performed with insertion of the acetabular component without cement and a precoat femoral component with cement. An average ten-year follow-up study. Clohisy JC, Harris WH. *J Bone Joint Surg Am.* 1999;81(2):247-55.
9. Hybrid total hip arthroplasty: 7- to 10-year results. Berger RA, Kull LR, Rosenberg AG, Galante JO *Clin Orthop Relat Res.* 1996;333:134-146.
10. Hybrid primary total hip arthroplasty: a 5- to 9-year followup study. Lewallen DG, Cabanela ME. *Clin Orthop Relat Res.* 1996;333:126-33.
11. NJR-NJR data from 1st April 2003 - 10th April 2018 on DePuy-Synthes products supplied for post-marketing surveillance, NJR Centre, 2018. Note: NJR-NJR Supplier Feedback data do not include Hospital Episode Statistics (HES) Data Linkage. Revisions may therefore be under-reported.
12. Lettin AWF, Ware HS, Morris RW Survival analysis and Confidence Intervals. An assessment with reference to the Stanmore total knee replacement. *J Bone Joint Surg Br.* 1991;73B(5):729-31.
13. National Joint Registry for England, Wales, Northern Ireland and the Isle of Man, 14th Annual Report, 2017. Table 3.6. Available from [www.njrreports.org.uk](http://www.njrreports.org.uk)
14. Australian Orthopaedic Association National Joint Replacement Registry. Annual Report, Adelaide; AOA 2017. Table HT19. Available from <http://aoanjrr.dmac.adelaide.edu.au/>

**Table HT19: Cumulative Percent Revision of Primary Total Conventional Hip Replacement by Fixation (Primary Diagnosis OA)**

Femoral Component	N Revised	N Total	1 yr	3 yrs	5 yrs	7 yrs	10 yrs	13 yrs
Cemented	121	5130	1.4 (1.1, 1.8)	2.1 (1.7, 2.6)	2.7 (2.2, 3.3)	3.7 (2.9, 4.7)		
Cementless	5955	179366	1.7 (1.7, 1.8)	2.6 (2.5, 2.7)	3.3 (3.2, 3.4)	4.9 (4.8, 5.1)	6.9 (6.5, 7.2)	7.0 (6.6, 7.4)
Hybrid	2383	93309	1.2 (1.1, 1.3)	1.9 (1.8, 2.0)	2.5 (2.4, 2.6)	3.9 (3.7, 4.1)	5.8 (5.2, 6.4)	6.0 (5.3, 6.9)
<b>Total</b>	<b>8459</b>	<b>277805</b>						

Note: Includes procedures using ceramic/ceramic and XLPE prostheses

15. New Zealand Joint Registry - Eighteen Year Report. 2017. Page 56. Available from <http://nzoa.org.nz/nz-joint-registry>
16. A prospective, randomized study of cross-linked and non-cross-linked polyethylene for total hip arthroplasty at 10-year follow-up. Engh CA Jr, Hopper RH Jr, Huynh C, Ho H, Sritulanondha S, Engh CA Sr. *J Arthroplasty.* 2012;27(8 Suppl):2-7.e1.

The data used for this analysis was obtained from the NJR Supplier Feedback System. All analyses of NJR data were undertaken by DePuy Synthes. The Healthcare Quality Improvement Partnership ('HQIP') and the National Joint Registry ('NJR') take no responsibility for the accuracy, currency, reliability and correctness of any data used or referred to in this report, nor for the accuracy, currency, reliability and correctness of links or references to other information sources and disclaims all warranties in relation to such data, links and references to the maximum extent permitted by legislation.

This publication is not intended for distribution in the USA.

The third-party trademarks used herein are trademarks of their respective owners.



Johnson & Johnson Medical Limited. Registered Office: Baird House, 4 Lower Gilmore Bank, Edinburgh, EH3 9QP. Incorporated and registered in Scotland under company number SC132162.

**DePuy Orthopaedics, Inc.**  
700 Orthopaedic Drive  
Warsaw, IN 46582  
USA  
Tel: +1 (800) 366 8143  
Fax: +1 (800) 669 2530

**DePuy International Ltd**  
St Anthony's Road  
Leeds LS11 8DT  
England  
Tel: +44 (0)113 270 0461

**DePuy (Ireland)**  
Loughbeg  
Ringaskiddy  
Co. Cork  
Ireland  
Tel: +353 21 4914 000  
Fax: +353 21 4914 199



[depuysynthes.com](http://depuysynthes.com)